ACADIA Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- ACADIA Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ACAD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001070494
- EIN
- 06-1376651
Board of directors
-
Adora Ndu · DirectorSince 2023
-
Catherine Owen Adams · Director · Chief Executive OfficerSince 2024
-
Daniel B. Soland · DirectorSince 2023
-
Edmund Harrigan · DirectorSince 2023
-
Elizabeth A. Garofalo · DirectorSince 2023
- Since 2023
-
James M. Daly · DirectorSince 2023
-
Jonathan Poole · DirectorSince 2026
- Since 2023
-
Laura Brege · DirectorSince 2023
-
Stephen Davis · Director · CEOSince 2023
Chief executives
Catherine Owen Adams
· Chief Executive Officer
Since September 2024
Stephen Davis
· CEO
Until September 2024
· Former
Director election results
Annual meeting of May 29, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
85.4%
Board connections
9 of this board's directors also sit on 23 other boards.
- via Adora Ndu, Daniel B. Soland, Felix Baker and Julian Baker
- via Edmund Harrigan, Felix Baker and Julian Baker
- via Felix Baker, James M. Daly and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Catherine Owen Adams
- via Elizabeth A. Garofalo
- via James M. Daly
- via Laura Brege
- via James M. Daly
- via Laura Brege
- via Laura Brege
- via Elizabeth A. Garofalo
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $3,401,275
- 24 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 6, 2026 | Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER) | Option exercise | +14,292 | $17.84 | $254,969 |
| Aug 6, 2026 | Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER) | Open-market sale | −5,000 | $29.00 | $145,000 |
| Aug 6, 2026 | Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER) | Open-market sale | −9,292 | $29.34 | $272,604 |
| Aug 5, 2026 | Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER) | Option exercise | +5,849 | $17.84 | $104,346 |
| Aug 5, 2026 | Schneyer Mark C. Officer (EVP, CHIEF FINANCIAL OFFICER) | Open-market sale | −5,849 | $29.00 | $169,638 |
| Jul 30, 2026 | Thompson Elizabeth H.Z. Officer (EVP, Head of Research & Dev) | Open-market sale | −16,508 | $26.13 | $431,354 |
| Jul 30, 2026 | Thompson Elizabeth H.Z. Officer (EVP, Head of Research & Dev) | Open-market sale | −50 | $26.17 | $1,309 |
| Jul 29, 2026 | Thompson Elizabeth H.Z. Officer (EVP, Head of Research & Dev) | Option exercise | +32,272 | — | — |
| Jun 26, 2026 | Kihara James Officer (PRINCIPAL ACCOUNTING OFFICER) | Open-market sale | −11,421 | $26.08 | $297,860 |
| May 29, 2026 | Baker Brothers Life Sciences LP Director, 10% owner | Grant or award | +18,622 | — | — |
| May 29, 2026 | Edmund Harrigan Director | Option exercise | +8,107 | — | — |
| May 29, 2026 | Adora Ndu Director | Option exercise | +8,107 | — | — |
| May 29, 2026 | Laura Brege Director | Option exercise | +8,107 | — | — |
| May 29, 2026 | Jonathan Poole Director | Option exercise | +2,010 | — | — |
| May 29, 2026 | Elizabeth A. Garofalo Director | Option exercise | +8,107 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.